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Deregulation of NOTCH1-signalling pathway is common in chronic lymphocytic leukemia (CLL). The most of studies are fo-
cused on detection of the hotspot c.7541_7542delCT NOTCH1 mutations in exon 34, while studies of mutations in the 3′UTR 
region are rare. The aims of work were to evaluate the frequencies of mutations in the 3′UTR region of the NOTCH1 gene 
(9:136,495553-136,495994) in Ukrainian CLL patients, the distribution of rs3124591 genotypes located in that area, and associa-
tion of NOTCH1 mutations with structure of B-cell receptor. Materials and Methods: Detection of mutations in the 3′UTR region 
of the NOTCH1 was performed by direct sequencing in 87 previously untreated CLL patients (from the total group of 237 CLL 
patients) with unmutated immunoglobulin heavy-chain variable (UM IGHV) genes and without mutations in hotspot regions of TP53, 
SF3B1, and exon 34 of NOTCH1 genes. Results: Mutations in the 3′UTR region of the NOTCH1 were revealed in three of 87 CLL 
patients (3.4%). Two cases with non-coding mutations were related to subset #1 of stereotyped B-cell receptors, and one case 
belonged to stereotyped subset #28a. Analysis with inclusion of 30 UM IGHV cases with previously detected c.7544_7545delCT 
mutations revealed that the frequency of UM IGHV genes of I phylogenetic clan (except IGHV1-69) was significantly increased, 
and the frequency of UM IGHV3 and IGHV4 genes, on the contrary, was reduced in NOTCH1-mutated cases comparing with 
NOTCH1-unmutated cases (p = 0.002) and the general group (p = 0.013). SNP rs3124591 did not affect the risk of CLL and 
survival parameters of the patients. At the same time, differences were found in the frequency of IGHV gene usage and in the 
structure of HCDR3 in carriers of individual genotypes. Conclusion: The frequency of NOTCH1 mutations in 3′UTR region was 
low. Our findings confirmed current data on the association between the structure of the B-cell receptor and the appearance 
of NOTCH1 mutations. Some features of HCDR3 structure were identified in carriers of TT and CC genotypes of rs3124591.
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Deregulation of NOTCH1-signalling pathway 
is common in chronic lymphocytic leukemia �CLL�. 
This gene encodes transmem�rane receptor� and 
active intracellular fragment of NOTCH� �ICN�� re-
leasing after ligand �inding� conformation changes 
and proteolytic cleavages translocates to the nu-
cleus� where it mediates the transcription of target 
genes involved in cell differentiation� proliferation 
and apoptosis [�� �]. Expression of ICN� was found 
in 5�.5% of CLL cases lacking NOTCH1 gene muta-
tions regardless of mutation status of immunoglo�ulin 
heavy-chain varia�le �IGHV� genes [3]. Prognostic 
significance of such constitutional ICN� expression 
in CLL is not yet known.
Activated NOTCH1 mutations in CLL were first found 
through whole-genome sequencing �y two independent 
groups in ���� [�� 5]. They were commonly represented 
�y a single �-�p deletion �c.�5��_�5�5delCT� P�5��fs� 
in exon 3� and resulted in the removal of C-terminal 
PE�T [proline �P�� glutamic acid �E�� serine ���� and 
threonine �T� rich] domain involved in proteasomal 
degradation of ICN�. NOTCH1 c.�5��_�5�5delCT 
mutations occur in ����% in newly diagnosed CLL� 
����5% at the time of first treatment and �5���% 
at chemorefractoriness and� according to the data 
of several authors� are associated with short progres-
sive-free �PF�� and overall survival �O�� [6� �]. Later� 
in the minority of CLL cases point mutations in the 
3´UTR region of NOTCH1 were found that resulted in the 
removal of C-terminal PE�T domain [�]. We revealed 
c.�5��_�5�5delCT mutations of NOTCH1 in �3.�% 
of untreated CLL patients. Associations �etween the 
presence of NOTCH1 mutations and unmutated �UM� 
IGHV genes� more advanced stage of the disease� 
higher initial WBC count� �ulky disease� short time-to-
treatment �TTT� period and PF� were found [9]. The 
aims of present work were to evaluate the frequencies 
of mutations in the 3´UTR region of the NOTCH1 gene 
�9:�36��95553��36��9599�� in Ukrainian CLL patients� 
the distri�ution of rs3���59� genotypes located in that 
area� and association of NOTCH1 mutations with struc-
ture of B-cell receptor.
MATERIALS AND METHODS
�amples of �� previously untreated CLL patients 
with UM IGHV genes and without mutations in hotspot 
regions of TP53� SF3B1, and NOTCH1 �exon 3�� 
genes were selected for the study from the total 
group of �3� patients. �uch choice of patients was 
�ased on the current data on a rare association 
of the NOTCH1 mutations with mutations of TP53 and 
SF3B1 genes� and their prevalence in cases with 
UM IGHV genes. All patients �69 males and �� females� 
were referred to the National Research Center for Ra-
diation Medicine� Kyiv� during the period of ��������6. 
The study was approved �y the local Ethics Review 
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Committee� and all patients gave informed consent 
prior to participation in it. The diagnosis of CLL was 
�ased on clinical history� lymphocyte morphology� and 
immunophenotypic criteria.
Genomic DNA for molecular analysis was ex-
tracted from peripheral �lood mononuclear cells with 
the QIAamp Blood Mini Kit �Qiagen� Crawley� United 
Kingdom� according to the manufacturer’s protocol. 
�creening for presence of TP53� SF3B1 mutations and 
NOTCH1 mutations in exon 3� as well as mutational 
status of IGHV genes was performed in all �3� patients.
IGHV-D-J rearrangements were ampliﬁed ac-
cording to the BIOMED-� consortium rules [��] 
as descri�ed previously [��]. IGHV rearrangements 
were analyzed �y IMGT/V-QUE�T [��]. Mutational 
status of TP53 gene was performed for exons 
3 to �� as descri�ed previously [�3]. SF3B1 muta-
tions were analyzed in exons ��� �5 and �6 �y PCR 
ampliﬁcation followed �y direct sequencing with the 
BigDye Terminator v3.� Cycle �equencing kit �Applied 
Biosystems� according to Rossi et al. [��]. It should 
�e noted that sequencing was carried out in those 
regions of TP53 and SF3B1 genes where the vast 
majority of mutations is located �> 95%� [�5� �6].
NOTCH1 mutations were analyzed in the hotspot 
c.����_�6�� region in exon 3� of NOTCH1 gene 
�y PCR amplification followed �y direct sequencing 
as descri�ed previously [9]. Detection of mutations 
in the 3´UTR region of NOTCH1 gene �9:�36��95553�
�36��9599�� was performed �y direct sequencing 
according to Puente et al. [�] using original prim-
ers. PCR conditions and primers are descri�ed in: 
dx.doi.org/��.��5��/protocols.io.qfhdtj6.
Analysis of rs3���59� genotypes was performed 
using �NPstats tool �http://�ioinfo.iconcologia.net/ 
snpstats/start.htm�.
TTT period� PF� and O� were estimated �y the 
method of Kaplan and Meier and assessed �y the 
log-rank test.
RESULTS
The frequency of NOTCH1 mutations and as-
sociation with HCDR3 structure. Mutations in the 
3´UTR region of the NOTCH1 were revealed in three 
of �� CLL patients �3.�%�. Non-coding mutations 
were represented �y �3939��5�T>C (two cases) and 
�3939���5T>C �one case�.
Two cases with non-coding mutations were related 
to su�set #� of stereotyped B-cell receptors� and one 
case �elonged to stereotyped su�set #��a �according 
to classifications of �tamatopoulos et al. [��]� Murray 
et al. [��]� Bom�en et al. [�9]�.
To study the associations of NOTCH1 mutations 
and the stereotyped B-cell receptors� we have added 
to the studied group 3� UM IGHV cases with previ-
ously revealed c.�5��_�5�5delCT mutations from 
the total group of �3� CLL patients. Thus� com�ined 
group of ��� UM-IGHV cases included 33 cases 
with NOTCH1 mutations and �� cases without 
NOTCH1 mutations in exon 3� and in the 3´UTR region. 
It was divided into three su�groups according to the 
principle used �y �utton et al. [��].
The frequency of NOTCH1 mutations in su�group 
of �� CLL cases with UM IGHV genes of I phylogenetic 
clan �comprising IGHV1, IGHV5 and IGHV7 genes�� 
except IGHV1-69� was the highest ��3 of �� cases; 
59.�%�. This su�group included 9 cases of su�set 
#� �five with NOTCH1 mutations�� � cases of su�set 
#��a ��oth NOTCH1-mutated�� one case of su�sets 
#59� #95� #UA/ref� [��] �all NOTCH1-mutated�� six 
cases showing homology with CLL sequences rep-
resented in the data�ases� �ut did not include in the 
stereotyped su�sets �three with NOTCH1 mutations�� 
and two NOTCH1-UM heterogeneous cases. Lengths 
of HCDR3 in NOTCH1-mutated cases varied from �� a.a. 
to �� a.a. and did not differ from NOTCH1-UM cases 
��5.66 ± �.9� a.a. vs ��.55 ± �.93 a.a.; p = �.�65�.
Additional NOTCH1-mutated CLL case� not includ-
ed in this su�group� in its structure of IGHV-D-J rear-
rangement was close to cases of su�sets #� �struc-
tures of HCDR3 in CLL cases with NOTCH1 mutations 
are availa�le �y request�.
In su�group of 3� CLL cases with UM IGHV1-69 gene� 
NOTCH1 mutations were revealed in �� cases �3�.�%�. 
NOTCH1-mutated cases �elonged to su�sets #6 �� of 3�� 
#9 �� of 3�� #UA/ref� �� of ��� #UA/ref�� �one case�. 
Additional one NOTCH1-mutated case was revealed 
among six cases homologous with CLL sequences 
represented in the data�ases� �ut did not include in the 
stereotyped su�types� and seven NOTCH1 mutations 
were found among fourteen CLL cases with heteroge-
neous HCDR3s. Without NOTCH1 mutations there were 
cases of su�sets #� �n = 5�� #UA� �n = ��� #UA6 �n = ��� 
and #UA� �n = ��. Lengths of HCDR3 in NOTCH1-
mutated cases varied from �� a.a. to �5 a.a. and did 
not differ from NOTCH1-UM cases ���.�� ± �.�5 a.a. 
vs ��.6� ± �.�� a.a.; p = �.635�.
In su�group of 5� CLL cases with other UM genes 
�IGHV3� n = 39; IGHV4� n = �6; IGHV2� n = �� NOTCH1 mu-
tations were present in seven cases ���.3%�. Two 
NOTCH1-mutated cases �elonged to su�sets 
#�� �� of 3� and #�5 �one case�� two had homology 
with CLL sequences represented in the data�ases� 
�ut not included in the stereotyped su�types �total 
n = �5�� the three remaining cases had heteroge-
neous HCDR3s �total n = �5�. CLL cases from su�sets 
#� �n = ��� #9 �n = ��� #3� �n = ��� #�� �n = ��� #�� �n = ��� 
#5� �n = ��� #��9 �n = ��� #UA5 �n = ��� and #UA9 �n = �� 
were NOTCH1-UM. Mean lengths of HCDR3 did not 
differ in NOTCH1-mutated ���.�� ± �.9� a.a.� and 
NOTCH1-UM cases ���.6� ± �.6� a.a.; p = �.�6��.
Differences in the frequency of NOTCH1 mutations 
in su�groups of cases expressed UM IGHV genes 
of I clan �except IGHV1-69�� IGHV1-69 gene and 
other UM IGHV genes were significant �p = �.����. 
The distri�ution of UM IGHV genes of the selected 
su�groups among NOTCH1-mutated cases was 
significantly different comparing with the distri�u-
tion in NOTCH1-UM cases� in the analyzed group 
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of ��� CLL cases as well as in total group of �3� CLL 
cases �Ta�le ��.
Table 1. The distribution of UM IGHV genes in studied CLL patients
Groups of CLL patients
Subgroups of UM IGHV genes p value 
in compa-
rison with 
NOTCH1-
mutated 
cases
Clan 
I except 
IGHV1-69
IGHV1-69
Other IGHV 
genes, in-
cluding 
IGHV6-1 
case
NOTCH1-mutated, n = 33 13 (39.4) 12 (36.4) 8 (24.2) –
NOTCH1-UM, n = 84 9 (10.8) 25 (27.7) 50 (59.5) 0.002
Whole group  
of 117 patients
22 (18.8) 37 (31.6) 58 (49.6) 0.013
161 cases with UM IGHV 
genes from total group 
of 237 patients
32 (19.9) 50 (31.0) 79 (49.1) 0.013
Analysis of rs3124591 SNP distribution and its as-
sociation with survival parameters and IGHV gene us-
age. The distri�ution of rs3���59� genotypes was as fol-
lows: CC genotype — �� cases ���.5%�� CT genotype — 
�� cases ���.�%�� and TT genotype — 3� cases �3�.�%� 
and did not deviate from the Hardy — Wein�erg equili�rium 
�p = �.���. In comparison with healthy individuals of Eu-
ropean ancestry retrieved from the ���� Genomes Proj-
ect dataset �CC genotype �6.�%; CT genotype ��.�%; 
TT genotype �6.�%; http://www.����genomes.org/� 
no significant differences were found. All three cases with 
non-coding NOTCH1 mutations were represented in car-
riers of TT genotype.
The impact of rs3���59� on duration of TTT period� 
PF� and O� was insignificant �p = �.��5� p = �.3��� 
and p = �.���� correspondingly�.
The spectrum of used  IGHV  genes tended 
to �e narrower in CC homozygotes than in carriers 
of CT and TT genotypes �correspondingly ��� ��� 
and � IGHV genes� p = �.��5; p = �.��3 in comparison 
TT vs CC genotype carriers� �Ta�le ��.
Table 2. The distribution of UM IGHV genes in carriers of different 
rs3124591 genotypes
IGHV genes Genotypes of rs3124591CC, n = 19 CT, n = 37 TT, n = 31
IGHV1 family 9 (47.4) 17 (45.9) 9 (29.0)
IGHV1-69 8 (42.1) 13 (35.1) 4 (12.9)
IGHV2 family 0 0 1 (3.2)
IGHV3 family 7 (36.8) 13 (35.1) 14 (45.2)
IGHV3-11 4 (21.1) 1 (2.7) 2 (6.5)
IGHV4 family 3 (15.0) 7 (18.9) 4 (12.9)
IGHV4-39 2 (10.5) 2 (5.4) 0
IGHV5 family 0 0 3 (9.7)
Expression of only two IGHV genes was detected 
in more than half of CC homozygotes �� cases with 
IGHV1-69 and � cases with IGHV3-11 gene�.We found 
a reduced IGHV1-69 gene usage in carriers of TT geno-
type compared to carriers of CT and CC genotypes 
���.9%� 35.�%� and ��.�%� correspondingly; 
p = �.�3��. The distri�utions of IGHD and IGHJ genes 
were compara�le in carriers of different genotypes. 
It should �e noted that the frequencies of IGHV and 
IGHJ genes usage and different stereotyped su�sets 
in this studied group did not differ from those in the 
previously studied large group cohort.
The HCDR3 length did not differ in carriers of dif-
ferent genotypes with UM IGHV genes �CC genotype 
��.�3 ± �.�� a.a.; CT genotype ��.�5 ± �.�3 a.a.; 
TT genotype �9.�6 ± �.�6 a.a.; p = �.����. However� the 
num�er of N nucleotides inserted in the VHD junctions 
was significantly less in carriers of TT genotype than 
in carriers of CT and CC genotypes �Ta�le 3�.
The comparison of CLL sequences with non-CLL 
sequences availa�le from pu�lic data�ases showed 
that most cases that had HCDR3 homology with anti-
�acterial or antiviral Ig clones were present in TT homo-
zygotes ���.6% vs �.�% in carriers of CT genotype and 
�% in carriers of CC genotype� p = �.��6; Ta�le ��. All 
CLL sequences homologous with autoreactive clones 
were revealed in carriers of TT �9.�%� and CT ���.�%� 
genotypes. A num�er of CLL cases that were similar 
to Ig sequences expressed �y normal B-cells �elderly� 
neonate� cord �lood� tonsils� and to Ig sequences from 
patients with X-linked hyperIgM did not differ in carriers 
of different rs3���59� genotypes �Ta�le 5� 6�.
Table 4. HCDR3 homology in carriers of different rs3124591 genotypes
HCDR3 homology with: Genotypes p valueCC CT TT
Normal B cells 4 (21.1) 10 (27.0) 5 (16.1) 0.515
Ig from X-HIgM syndrome 0 1 (2.7) 3 (9.7) 0.226
Antibacterial or antiviral Ig clones 0 1 (2.7) 7 (22.6) 0.006
Autoreactive clones 0 4 (10.8) 3 (9.7) 0.332
DISCUSSION
To investigate non-coding mutations in the 
3´UTR region of the NOTCH1� previously untreated 
CLL cases with no mutations in TP53� SF3B1, 
and NOTCH1 �exon 3�� genes were selected. All 
Table 3. N-nucleotide additions and exonuclease activities in the VHD and DJH junctions in carriers of different rs3124591 genotypes
Parameters Genotypes p valueCC CT TT
VHD N-nucleotide addition (bp) 8.68 ± 1.05 9.33 ± 1.01 5.56 ± 0.83 0.014
VHD with no addition (% of sequences) 0 8.1 16.1 0.144
VHD N-nucleotide addition (bp) except cases with no addition 8.68 ± 1.05 10.18 ± 0.96 6.68 ± 0.83 0.032
DJH N-nucleotide addition (bp) 10.21 ± 2.19 7.72 ± 0.95 8.56 ± 1.10 0.443
DJH with no addition (% of sequences) 0 10.8 3.22 0.190
DJH N-nucleotide addition (bp) except cases with no addition 10.21 ± 2.19 8.68 ± 0.94 8.86 ± 1.10 0.716
VH 3' coding end excision (bp) 1.56 ± 0.19 1.63 ± 0.25 1.73 ± 0.43 0.542
VH 3' without excision (% of sequences) 36.8 27.03 38.71 0.415
VH 3' coding end excision (bp) except cases without excision 1.83 ± 0.29 2.26 ± 0.27 3.05 ± 0.60 0.157
D 5' coding end excision (bp) 5.11 ± 1.10 4.33 ± 0.61 4.23 ± 0.85 0.762
D 5' without excision (% of sequences) 0 16.2 25.8 0.049
D 5' coding end excision (bp) except cases without excision 5.11 ± 1.10 5.20 ± 0.62 5.77 ± 0.96 0.848
D 3' coding end excision (bp) 5.05 ± 0.77 5.00 ± 0.71 3.73 ± 0.72 0.365
D 3' without excision (% of sequences) 15.8 18.9 22.6 0.808
D 3' coding end excision (bp) except cases without excision 6.00 ± 0.68 6.21 ± 0.72 4.86 ± 0.79 0.395
JH 5' coding end excision (bp) 3.00 ± 0.87 3.66 ± 0.59 4.10 ± 0.64 0.581
JH 5' without excision (% of sequences) 26.3 27.03 22.58 0.918
JH 5' coding end excision (bp) except cases without excision 4.07 ± 1.04 5.07 ± 0.62 5.34 ± 0.62 0.510
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of them expressed UM IGHV genes. �uch choice 
was due to the literature data on a rare association 
of the NOTCH1 mutations with mutations of the other 
genes. In addition� NOTCH1 mutations are mainly 
detected in CLL patients with UM IGHV genes. For 
example� in the study of Rossi et al. �6.5% of CLL 
cases with NOTCH1 mutations in exon 3� expressed 
UM IGHV genes� and more than 9�% of them did 
not have mutations of TP53 gene [6]. In the study 
of �chnaiter et al.� in none of 9� fludara�ine-refractory 
CLL patients concurrent NOTCH1 and SF3B1 were 
found� �ut �3.�% of NOTCH1-mutated cases had 
simultaneously TP53 gene mutations. All revealed 
NOTCH1 mutations in this study were in patients with 
UM IGHV genes [��]. In our group of �3� CLL patients� 
mutations of TP53� SF3B1� and c.�5��_�5�5delCT 
of NOTCH1 were found in ��.�%� ��.�%� and �3.�% 
of cases� correspondingly. Only single case har�ored 
mutations in �oth NOTCH1 and TP53 genes and two 
cases — in NOTCH1 and SF3B1 gene. All except 
one NOTCH1-mutated cases had UM IGHV genes. 
Therefore� we investigated a group of CLL patients 
with an increased chance to identify mutations in the 
3´UTR region of NOTCH1 gene.
Non-coding mutations in the 3´UTR region 
of NOTCH1 gene were first identified �y Puente 
et al. [�]. Authors revealed �� NOTCH1 mutated cases 
of ��6 CLL patients with UM IGHV genes �6.�%�. The 
most frequent recurrent non-coding mutation was 
�3939��5�T>C� and two cases had �3939���5 and 
�3939���3 point mutations. Nadeu et al. detected 
3´UTR mutations in �� of 39� CLL patients �5.6%� [�3]. 
We have identified two cases with �3939��5�T>C muta-
tion and one case with �3939���5T>C mutation among 
�� IGHV-UM CLL cases �3.�%�. The frequency of non-
coding mutations in our group and their localization 
were compara�le with previously pu�lished data.
Our data confirmed current data on the associa-
tion �etween the structure of the B-cell receptor and 
appearance of NOTCH1 mutations. In one of the larg-
est series of studied stereotyped su�set CLL cases 
�565 cases assigned to one of �� major stereotyped 
su�sets� the skewed distri�ution of NOTCH1 muta-
tions within exon 3� was found. Enriched mutations 
were cases �elonged to su�sets #�� #59� #99� #6� 
and #�. NOTCH1 mutations were relatively infrequent 
in cases from su�sets #3� #5� #� and� especially� from 
su�sets #� and #� [��]. In our group� five of the nine 
cases from stereotyped su�set #� were NOTCH1-
mutated: three had mutations within exon 3� and 
two had non-coding mutations in the 3´UTR region. 
On the contrary� NOTCH1 mutations were not found 
among nine cases of su�set #�. The num�er of cases 
�elonged to other su�sets was too low for comparison. 
However� the o�served differences in the frequency 
of NOTCH1 mutations in su�groups of cases that 
expressed UM IGHV genes of I clan �except IGHV1-
69)� UM IGHV1-69 gene and other UM IGHV genes 
�59.�%� 3�.�%� ��.3%� correspondingly� cannot 
�e explained solely �y the presence in the first su�-
group of the cases �elonged to su�set #�. Excluding 
cases of su�set #�� NOTCH1 mutations were detected 
in eight of �� remaining cases of the first su�group 
���.�%�. Both cases of su�set #��a were NOTCH1-
Table 5. Structure of HCDR3 region in CLL cases with NOTCH1 mutations (MAS — mean alignment score)
CLL cases HCDR3 amino acid sequence Subset
1-03*01_6-19*01_4*02_UM_EF407847 AREQWLGPSYFDY 1
1-02*02_6-19*01_4*02_UM_EU350413 ARAQWLVQLSLDY 1
1-02*02_6-19*01_4*02_UM_S42 ARLQWLWPRKLDY 1
5a*01_3-22*-1_4*02_UM_EF441753 ARIQWLLLPHFDY 1
5a*03_3-16*-1_4*02_UM_KC802107 ARLQFLGISDPFDY 1
1-02*02_1-26*01_6*02_UM_EF091912 ARPYSGSYPWYYYGMDV 28a
1-02*02_3-10*01_6*02_UM_EU667602 ARLYSGSYFYYYYGMDV 28a
1-58*01_3-3*01_6*02_UM_EF091913 AAGYDFWSGMDV 59
1-02*02_3-22*01_4*02_UM_GU358667 ERSYDSSGYYCHFDY 95
1-58*01_6-13*01_3*02_UM_EF175413 ALASSWIFDAFDI UA/ref4
1-02*04_2-8*01_6*02_UM_EU433868 AKPSFYCTNGVCYTDYYYGMDV Homology with CLL cases DQ100687 (MAS 68.2), EF177969 (MAS 68.2)
1-46*01_3-9*01_5*02_UM_GU358664 ARDRGYFDWLLRNGWFDP Homology with CLL case EF441746 (MAS 72.2)
5-51*01_3-3*01_4*02_UM_JQ928948 ARHGMYYDFWSGYYLAAYFDY Homology with CLL cases EU099117 (MAS 66.6); DQ100922 (MAS 61.9)
6-1*01_6-19*01_4*02_UM_JF810281 ARDEYWGSGWDY
1-69*06_3-16*02_3*02_UM_GU358670 ARGGDYDYIWGSYRSNDAFDI 6
1-69*01_3-3*01_6*02_UM_EF407834 ASKSLPITIFGVVISDYYYYGMDV 9
1-69*01_6-13*01_6*02_UM_EF175412 ARVQGGSAAAYENYYYYYGMDV UA/ref2
1-69*01_2-2*02_5*02_UM_EU350410 AREFSDIVVVPAAIIRNWFDP UA/ref11
1-69*01_3-3*01_6*02_UM_EU667595 ARAPDFWSGYYFRGGGMDV Homology with CLL case DQ100846 (MAS 68.4)
1-69*01_2-2*02_6*01_UM_EU433873 AREGGDIVVVPAAIISWSRYYGMDV
1-69*01_3-22*01_4*02_UM_S9 ARWGGGAYYYDSSGYYYGFDYYFDY
1-69*01_3-22*01_5*02_UM_KC02101 ARRNSGYYYYKEYNWFDP
1-69*01_3-9*01_4*02_UM_EF441755 ARDSRELRYFDWLSQEGYFDY
1-69*13_5-24*01_6*02_UM_GU358657 AREGDGYNYGYYYYYGMDV
1-69*01_6-19*01_6*03_UM_JX462742 ARVGGYSSGWYQNYYYYYMDV
1-69*01_3-9*01_4*02_UM_HM173329 VRMHFDWLRPAFYSFDY
3-11*01_3-3*01_6*02_UM_EF175391 ARTYYDFWSGYDGHYGMDV 22
3-30*03_3-3*01_6*02_UM_EU814961 AKDGLGIRFLEWLSTSYYYGMDV 25
4-04*02_2-2*01_5*02_UM_EU350427 ARVPIVVVPAAVSLMRVNWFDP Homology with CLL case EU099080 (MAS 77.2)
4-34*01_6-6*01_6*03_UM_GU358661 ARGLTYSSSSYYYYYYMDV Homology with CLL case EF407849 (MAS 68.4)
3-53*01_3-3*01_6*02_UM_EF175410 ARDASPSLYYDFYPYGMDV
3-64*05_6_19*01_2*01_UM_HM173330 VKDSTPGIAVAGTWGYWYFDL
2-70*01_3-3*01_4*02_UM_S10 ARTTKLSVYDFWSGYYTGSGLGYFDY
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Table 6. CLL cases showing HCDR3 homology with immunoglobulins of known specificity (MAS — mean alignment score)
IGHV gene HCDR3 amino acid sequence MAS Subset Antigen specificity
CC genotype
3-11*01_3-3*01_6*02_UM_LM647765 ARA--YDFWSGY-YFERYGMDV Peripheral blood B lymphocyte
3-11*01_3-3*02_6*02_UM_JQ928963 ARWGPYDFWSGYSYYYYYGMDV 68.1 22
1-69*01_2-2*01_6*02_UM_AB204177 AR_GGYCSSTSCTILSYYYYGMDV Umbilical cord blood CD19+IgD+CD27-CD38+ 
B lymphocyte
1-69*01_2-2*02_6*04_UM_JX462747 ARWSGYCSSTSCMGADYYYYGMDV 75.0
4-39*01_3-10*01_5*02_UM_AY607328 ARRLSYYYGSGSYYNWFDP Term cord blood
3-11*01_3-10*01_5*02_UM_JQ928962 ARDNVLYYGSGSYFNWFDP 73.0
4-34*01_3-3*01_6*03_UM_LM647851 ARGRVGYDFWSGS-PYYYYYYMDV Peripheral blood B lymphocyte
1-69*01_3-3*01_6*03_UM_KC802110 ARGRN-YDFWSGPTWGYYYYYMDV 73.0 7
TC genotype KC802096
4-34*01_2-2*02_4*02_UM_AY607318 ARTIIVVVPAAIRWFDP Term cord blood
4-34*01_2-2*02_4*02_UM_KC802096 AREDIVVVPAALYYFDY 70.6
3-11*04_3-10*01_4*02_M_AB202917 ARDSLWFGEFMY--FDY Tonsillar B cell
3-11*01_3-10*01_4*02_UM_EU433870 ARDTLWFGEFHAYYFDY 70.6 UA/ITA_13
1-8*01_-0*01_3*02_UM_EU571887 ASVLGTYYYGSGSYYDAFDI IgM+ B lymphocyte 18 week gestation fetus 
spleen
4-30-4*01_3-0*01_3*02_UM_GU358680 ARK--TYYYGSGSYYDAFDI 77.7
6-1*01_6-6*03_6*03_UM_LM648697 AREGSSWSGNYYYYYYMDV Peripheral blood B cell
3-49*03_6-13*01_6*-3_UM_EF175429 TSHSSSWDYYYYYYYYMDV 63.1
3-33*01_6-19*01_6*02_UM_AF174112 ARDRLAVAGTVYYYYGMDV Elderly B cell
3-33*01_4-11*01_6*02_UM_EF407833 ARDLHAVTTRNYYYYGMDV 68.4 44
3-07*1_3-22*01_6*01_UM_DQ454347 ARV-GDYYDSSGYYYYYYGMDV Neonate peripheral blood
4-59*_3-22*01_6*02_UM_GU358662 ARGLGDYYDSSGYLHYYYGMDV 81.8 50
3-33*01_3-3*01_6*02_UM_AY607518 ARDTPY-DFWSGYYYYYYGMDV Term cord blood
3-33*01_3-3*01_6*02_UM_JX462745 ARDTRVDDFWSGYFVYYYGMDV 77.0 22
3-30*03_3-22*01_6*02_UM_LM648585 ARDWASRDSSGYYYL-GYYYYMDV Peripheral blood B cell
3-07*1_3-22*01_6*02_UM_EU814965 ARDTYYYDSSGYYYPYYYYYGMDV 65.0
1-69*01_2-2*01_6*02_UM_LM648973 ARDS--DIVVVPAARGPYYYGMDV Peripheral blood B cell
1-69*01_2-2*01_6*02_UM_EF091906 ASPGPQDIVVVPAAYYYYYYGMDV 79.0
1-8*01_2-2*01_6*02_UM_AJ414783 AR--VTGYCSSTSCTKVYYYYYGMDV B cell
3-21*-1_2-2*01_6*02_UM_EF091902 ARNRYTEYCSSTSCHPSYYYYYGMDV 73.0 41
3-33*01_3-3*01_6*02_UM_EF541600 ARDISTDFWSGYYT--GSYYYGMDVW Ig in X-HIgM Syndrome patient
1-2*01_3-3*01_6*02_UM_EU667601 ARGVSYDFWSGYYIREGDYYYGMDV 72.0 7D
5-10-1*01_3-10*01_3*02_M_JF274048 ARRATYYYGSGSYFDAFDI Anti-Influenza H5N1 Viruses
4-30-4*01_3-0*01_3*02_UM_GU358680 AR-KTYYYGSGSYYDAFDI 89.7
1-69*13_2-2*01_6*02_UM_U86795 AGT-IVVVPAAGGIFFYYYGMDV Heterohybridoma derived from CD5+ CLL B lym-
phocytes with rheumatoid factor activity
1-69*01_2-2*01_6*02_UM_HM173323 ARTDIVVVPAAMII-YYYYGMDV 72.7
1-69*06_3-16*02_3*02_UM_AF460965 ARGGNYDYIWGSYRSNDAFDI Antiphospholipid antibodies
1-69*01_3-16*02_3*02_UM_EF091909 ARGGDYDYIWGSYRPNDAFDI 90.5 6
1-69*01_3-16*02_3*02_UM_GU358676 ARGGNYDYIWGSYRTNDAFDI 95.0 6
PH0955 ARVSIFGVVQHYYYYYYMDV Rheumatoid factor
1-69*01_3-3*01_6*02_UM_KC802106 ARVQVFGVVNTYYYYYYMDV 80.0
TT genotype
4-34*01_3-3*01_6*03_UM_LM647851 ARGRVGYDFWSGS-PYYYYYYMDV Peripheral blood B cell
4-34*01_3-3*01_6*03_UM_EF091922 ARGFGYYDFWSGTHPPNYYYYMDV 70.8
3-21*01_6-13*01_6*02_UM_LM647465 ARDQGSSSSWFDYYYYGMDV Peripheral blood B cell
3-21*01_6-13*01_6*02_UM_EF091900 ARDRGVSSSWYLSYYYYMDV 70.0 26
1-8*01_6-13*01_4*01_UM_LM647894 AR-GARYSSSWYPFDY Peripheral blood B cell
3-30*01_6-13*01_4*01_UM_HM173331 ARVGTGYSSSWYPFDY 81.0
3-74*02_3-3*01_6*02_UM_LM647144 AAIYDFWSGYWSYYYYYGMDV Peripheral blood B cell
3-48*03_3-3*01_6*02_UM_JQ928950 ARDYDFWSGYYAYYYYYGMDV 31 80.9
3-7*01_3-3*01_6*02_UM_LM648392 ARGLYDFWSGYYPHYYYYGMDV Peripheral blood B cell
1-69*01_3-3*01_6*02_UM_S17 AAQ--DFWSGYYPHYYYYGMDV 60.0
3-64*01_2-2*03_6*02_UM_EF541666 ARDGYCSSTSCYLDGGLYYYY-GMDV Ig from X-HIgM patient
1-2*04_2-15*01_6*02_UM_JF810257 AREGYCSGGSCYPPPGNYYYYYGMDV 69.0 UA/ITA_17
3-48*02_3-3*01_6*02_UM_AF077457 ARDSTIFGVVII-DYYYGMDV Ig from X-HIgM patient
3-30*03_3-3*01_6*02_UM_EU433876 RAQM-IFGVVIIEDYYYGMDV 70.0 9
3-30*03_-3*01_6*02_UM_EF542369 ASHYDFWSGHYEPYYYYGMDV Ig from X-HIgM patient
3-48*03_3-3*01_6*02_UM_JQ928950 ARDYDFWSGYYAYYYYYGMDV 31 80.9
1-2*04_3_3*01_6*02_UM_AY686915 ARES--YYDFWSGKRN-YYYYGMDV Anti-rotavirus Ig
1-2*04_3_3*01_6*02_UM_EU433869 ARDGLQYYDFWSGSDLAYYYYGMDV 68.0 7D
3_11*05_3-3*01_5*02_UM_DQ322854 ARDTRPYDFWSGYYP-NWFDP Anti-pneumococcal polysaccharides Ig
4-61*01_3-3*01_5*02_UM_EF091926 ARHRGDYDFWSGYYPYNWFDP 80.9 UA_5
4-59*01_3-3*01_6*03_UM_FJ385336 ARDLTYYDFWSGYYPDYYYY-MDV Anti-respiratory syncytial virus Ig
4-34*01_3-3*01_6*03_UM_EF091922 ARGFGYYDFWSGTHPPNYYYYMDV 66.6
1-2*02_1-26*01_6*02_UM_AY944713 ARVYSGSYPYYYYGMDV Anti-rotavirus Ig
1-2*02_1-26*01_6*02_UM_EF091912 ARPYSGSYPWYYYGMDV 88.0 28
3-21*01_6-13*01_6*02_UM_KJ409179 ARDKEYSSSWYLYPYYYYMDV Anti-HCV Ig
3-21*01_6-13*01_6*02_UM_EF091900 ARDRGVSSSWYL-SYYYYMDV 75.0 26
1-18*01_1-26*01_4*02_M_JX213637 ARDVQYSGSYLGAYYFDY Anti-influenza B viruses Ig
4-59*01_1-26*01_4*02_UM_JX462751 ARHDPYSGSYLV-YYFDY 70.5
3-11*01_3-3*01_5*02_UM_DQ322847 ARDTRPYDFWSGYYP-NWFDP Anti-pneumococcal polysaccharides Ig
3-11*01_3-3*01_5*02_UM_EU667604 ARD-R-YDFWSGYIGYNWFDP 73.6 UA_5
4-34*01_3-3*01_4*02_UM_X54441 ARGGSVLRFLEWLLYPAFDY Rheumatoid factor
1-69*01_3-3*01_4*02_UM_EU667599 ARSGE-LRFLEWLLSADFDY 68.4 UA_7
3-33*01_4-17*01_3*02_UM_AJ305181 AKGDYGDYSFAFDI Anti-SLE Ig
3-33*01_4-17*01_3*02_UM_EF407846 ARGVPGDYVMAFDI 71.0 UA_9
3-30-3*01_4-17*01_3*02_UM_EF407832 ARGPRGDYVSSFDL 57.0 UA_9
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mutated �mutations within exon 3� and non-coding 
region�. The occurrence of UM IGHV genes of I clan 
�except IGHV1-69) among NOTCH1-mutated cases 
was twice as high as in the general group. Therefore� 
it can �e suggested that expression of UM IGHV genes 
of I clan �except IGHV1-69) is a risk factor for the 
presence of NOTCH1 mutations. On the contrary� the 
pro�a�ility of detecting NOTCH1 mutations was lower 
in the carriers of other UM genes �it should �e noted 
that su�set #� was a�sent in our cohort�.
When searching for non-coding mutations 
in the 3´UTR region of the NOTCH1� we paid attention 
to rs3���59�� which is localized in the amplified region. 
Preliminary data suggested its functional signifi-
cance. Quan et al. found association of CC genotype 
of rs3���59� ��6.�% among cases and ��.�% in the 
control group� with the risk of lung cancer in north-
east Chinese non-smoking females [��]. In study 
of Gao et al.� also performed in Chinese population� 
CC genotype of rs3���59� was a�sent in the control 
group �n = ���� and among patients with invasive 
ductal carcinoma �IDC� n = ���� and ductal carcinoma 
in situ �DCI�� n = 5�� [�5]. The C allele was significantly 
associated with high risk of DCI�� �ut not IDC; the 
TC genotype was significantly associated with an in-
creased risk of IDC and DCI� and poorly differentiated 
IDC. In addition� Notch� protein expression was signifi-
cantly higher in DCI� patients with the TC genotype. 
Although Notch� protein expression was higher in IDC 
patients with the TC genotype� this association did not 
reach significance. Authors concluded that the impact 
of the rs3���59� variant on Notch� protein expression 
mainly occurs early in IDC development.
In our study� rs3���59� did not affect the risk of CLL 
and survival parameters of patients. At the same time� 
differences were found in the frequency of IGHV gene 
usage and in the structure of HCDR3 in carriers of indi-
vidual genotypes. Leukemic cells of CC homozygotes 
expressed the most limited spectrum of UM IGHV 
genes �mostly IGHV1-69 and IGHV3-11�� and their 
HCDR3 sequences were homologous only with the 
sequences of normal B-cells. Conversely� leukemic 
cells of TT homozygotes used the largest num�er 
of UM IGHV genes� more frequently had HCDR3 ho-
mology with anti�acterial or antiviral Ig clones� had 
less N nucleotide additions in DJH junctions� and the 
num�er of sequences that lacked N additions at DJH 
junctions had a tendency to �e higher. By two last 
parameters� they were a �it like a memory B cells� 
characterized �y Tian et al. [��]. It is known that 
Notch� signaling regulates B and T lymphocyte de-
velopment [���3�]. Taking into account data of Cao 
et al. [�5] on the functional significance of rs3���59�� 
we hypothesized that rs3���59� could influence on the 
selection of B-cell clones during early stages of CLL 
development. This assumption are in an agreement 
with reports regarding the role and possi�le mecha-
nisms of NOTCH signaling in regulation of the normal 
B-cell repertoire� summarized �y Cruickshank and 
Ulgiati [3�].
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